{"transactions":[{"id":1067637,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-08-13T22:03:44.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":22073,"price":5.1517,"value":113713.4741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":221799,"source":{"system":"sec-edgar","filing":"0000950170-25-108210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025108210/ownership.xml","form_type":"4"}},{"id":1219224,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-06T21:13:41.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":202427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2025."}],"balance_after":202427,"derivative":{"exercise_price":6.17,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":202427},"source":{"system":"sec-edgar","filing":"0000950170-25-034648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025034648/ownership.xml","form_type":"4"}},{"id":1433448,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-08-14T20:24:22.000Z","date":"2024-08-12","kind":"sale","planned":false,"acquired":false,"shares":16041,"price":4.7363,"value":75974.9883,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $4.46 to $5.12. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":236771,"source":{"system":"sec-edgar","filing":"0000950170-24-097071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024097071/ownership.xml","form_type":"4"}},{"id":1539772,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-04-17T20:12:37.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":11537,"price":3.164,"value":36503.068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the \"Original Form 4\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Adjusted to reflect 9,317 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment."}],"balance_after":252812,"source":{"system":"sec-edgar","filing":"0000950170-24-045113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024045113/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-12"}},{"id":1580569,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T00:04:43.000Z","date":"2024-03-09","kind":"grant","planned":false,"acquired":true,"shares":405450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024."}],"balance_after":405450,"derivative":{"exercise_price":3.62,"expiration_date":"2034-03-08","underlying":"Common Stock","underlying_shares":405450},"source":{"system":"sec-edgar","filing":"0000950170-24-030311","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030311/ownership.xml","form_type":"4"}},{"id":1580568,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:43.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":11537,"price":3.164,"value":36503.068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":243495,"source":{"system":"sec-edgar","filing":"0000950170-24-030311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030311/ownership.xml","form_type":"4"}},{"id":1580567,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:43.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":18231,"price":3.4064,"value":62102.0784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":255032,"source":{"system":"sec-edgar","filing":"0000950170-24-030311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030311/ownership.xml","form_type":"4"}},{"id":1978911,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T21:27:10.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":220258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023."}],"balance_after":220258,"derivative":{"exercise_price":6.76,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":220258},"source":{"system":"sec-edgar","filing":"0000899243-23-006748","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924323006748/doc4.xml","form_type":"4"}},{"id":2205124,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Bonus Units","published_at":"2022-07-19T20:34:10.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":69473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."}],"balance_after":69473,"derivative":{"underlying":"Common Stock","underlying_shares":69473},"source":{"system":"sec-edgar","filing":"0000899243-22-026344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322026344/doc4.xml","form_type":"4"}},{"id":2205123,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2022-07-19T20:34:10.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":185605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":273263,"source":{"system":"sec-edgar","filing":"0000899243-22-026344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322026344/doc4.xml","form_type":"4"}},{"id":2310879,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-01T23:37:08.000Z","date":"2022-03-30","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022."}],"balance_after":250000,"derivative":{"exercise_price":4.52,"expiration_date":"2032-03-29","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-22-013173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322013173/doc4.xml","form_type":"4"}},{"id":2310878,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2022-04-01T23:37:08.000Z","date":"2022-03-30","kind":"grant","acquired":true,"shares":64395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,972 shares previously purchased under the Issuer's Employee Stock Purchase Plan."}],"balance_after":87658,"source":{"system":"sec-edgar","filing":"0000899243-22-013173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322013173/doc4.xml","form_type":"4"}},{"id":2749393,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-14T23:24:10.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":116201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021."}],"balance_after":116201,"derivative":{"exercise_price":11.71,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":116201},"source":{"system":"sec-edgar","filing":"0000899243-21-015838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924321015838/doc4.xml","form_type":"4"}}]}